Abstract
De Bono et al. (May 26 issue)1 report that the CYP17 inhibitor abiraterone increased survival in patients with metastatic castration-resistant prostate cancer. However, CYP17 inhibition leads to a corticotropin-induced mineralocorticoid excess that needs to be efficiently counteracted.2 In this study, such hormone derangement was mitigated but not abolished by the concomitant administration of prednisone. A greater incidence of hypokalemia and fluid retention was seen in patients receiving abiraterone plus prednisone than in those receiving placebo plus prednisone, and this may have contributed to the greater cardiac toxicity observed. It would be interesting to know how the investigators managed these side effects and the results obtained. In particular, was the prednisone dose increased? Were mineralocorticoid-receptor blockers introduced? Because of its intrinsic mineralocorticoid activity,3 prednisone may be not the best drug to be used in this context, and the potential introduction of dexamethasone as an alternative should be discussed.2 Finally, the authors should discuss the utility of monitoring serum corticotropin levels during abiraterone treatment in order to adjust the supplementation therapy on an individual basis.